Aspirin composition for treating coronary heart disease and preparation method of aspirin composition

Abstract

The invention discloses an aspirin composition for treating the coronary heart disease and a preparation method of the aspirin composition. The aspirin composition comprises, by weight, 3-7 parts of aspirin, 20-25 parts of processed pinellia ternate, 30-35 parts of agilawood, 60-70 parts of radish seeds, 35-40 parts of fresh ginger, 25-30 parts of monkshood, 50-60 parts of red dates and 80-100 parts of pharmaceutic adjuvants. The preparation method includes Chinese herbal medicine raw material preparation, extraction of active ingredients of traditional Chinese medicine raw materials, pelletizing, pellet arrangement and tabletting. The aspirin composition is capable of not only treating the coronary heart disease but also invigorating the stomach, and is capable of enhancing functions of the spleen, the stomach and intestines and benefiting to absorption and efficacy of the aspirin by means of synergism of the processed pinellia ternate, the fresh ginger, the monkshood, the agilawood, the radish seeds and the red dates. By the aid of the red dates and the fresh ginger, toxic and side effect of the aspirin, the processed pinellia ternate, the monkshood, the agilawood, the radish seeds and the like can be reduced. The aspirin composition which is a sustained release preparation is taken once every day and is convenient to take and beneficial to improvement in patients' compliance.

Description

technical field [0001] The present invention relates to the field of compositions used in combination with Chinese and Western medicines, in particular to an aspirin composition for treating coronary heart disease and a preparation method thereof Background technique [0002] Aspirin is the earliest antiplatelet drug used in antithrombotic therapy, and has been established as a classic drug for the treatment of acute myocardial infarction (AMI), unstable angina and secondary prevention of myocardial infarction (MI). The principle of action is that aspirin irreversibly acetylates the hydroxyl group of the 529th serine residue in the COX-1 active site polypeptide chain in the cyclooxygenase, leading to the inactivation of COX, and then blocking the conversion of AA into thromboxane A2 (TXA2) pathway to inhibit PLT aggregation. COXs are the key rate-limiting enzymes in the process of producing TXA2 and prostaglandin I2 (PGI2) from AA. There are two forms of COX-1 and COX-2 in ...

AI Technical Summary

Problems solved by technology

[0004] In order to overcome the damage of aspirin to the gastric mucosa, some people make aspirin into enteric-coated tablets. Enteric-coated tablets avoid the direct stimulation of aspirin to the gastric mucosa, but they cannot solve the stimulation of aspirin to the intestinal mucosa, and the general patients with coronary heart disease who need long-term medication For the elderly over 50 years old, the elderly's gastrointestinal function is relatively weak, or they suffer from chronic gastroenteritis, etc.

Images